OKYO Pharma (OKYO) Stock Price, News & Analysis

Company Overview

Okyo Pharma Inc. is a clinical-stage biopharmaceutical company focused on developing novel therapies for inflammatory and fibrotic diseases. The company’s pipeline is built on proprietary Fc-fusion technology designed to modulate immune responses associated with conditions such as diabetic nephropathy and chronic graft-versus-host disease. Okyo Pharma seeks to address significant unmet medical needs by targeting key cytokine pathways involved in tissue inflammation and fibrosis.

Okyo Pharma’s lead product candidate, OK-101, is an Fc-fusion protein in Phase 2 development for the treatment of diabetic kidney disease. The company’s second program, OK-202, is advancing in preclinical studies for chronic graft-versus-host disease, with plans to expand into other fibrotic indications. These programs leverage the company’s expertise in biologics engineering to deliver enhanced therapeutic profiles, including improved half-life and tissue targeting.

Founded through a combination of biotechnology collaborations and strategic financing, Okyo Pharma completed its initial public offering on the NASDAQ under the ticker symbol OKYO. Headquartered in the United States, the company has established research partnerships across North America and Europe to support its clinical development efforts. Leadership is headed by Chief Executive Officer Thomas Baum, Ph.D., who brings extensive experience in biologics development and regulatory strategy.

Key Stats

• Today's Range: $2.16 to $2.23
• 50-Day Range: $2.20 to $3.27
• 52-Week Range: $0.90 to $3.35
• Volume: 13,295 shs
• Average Volume: 165,170 shs
• Market Capitalization: $81.99 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $7.00
• Consensus Rating: Buy

OKYO Pharma Stock Analysis - MarketRank™

OKYO Pharma scored higher than 52% of companies evaluated by MarketBeat, and ranked 521st out of 923 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

OKYO Pharma has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.

Upside Potential

OKYO Pharma has a consensus price target of $7.00, representing about 221.1% upside from its current price of $2.18.

Amount of Analyst Coverage

OKYO Pharma has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Earnings Growth

Earnings for OKYO Pharma are expected to remain at ($0.17) per share in the coming year.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.07% of the float of OKYO Pharma has been sold short.

Short Interest Ratio / Days to Cover

OKYO Pharma has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in OKYO Pharma has recently decreased by 79.95%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

OKYO Pharma does not currently pay a dividend.

Dividend Growth

OKYO Pharma does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

0.07% of the float of OKYO Pharma has been sold short.

Short Interest Ratio / Days to Cover

OKYO Pharma has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in OKYO Pharma has recently decreased by 79.95%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 2.2 / 5
• News Sentiment: N/A

News Sentiment

OKYO Pharma has a news sentiment score of 0.93. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.

News Coverage This Week

MarketBeat has tracked 1 news article for OKYO Pharma this week, compared to 1 article on an average week.

Search Interest

Only 1 people have searched for OKYO on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.

MarketBeat Follows

11 people have added OKYO Pharma to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, OKYO Pharma insiders have not sold or bought any company stock.

Percentage Held by Insiders

40.46% of the stock of OKYO Pharma is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

Only 2.97% of the stock of OKYO Pharma is held by institutions.

OKYO Stock Analysis - Frequently Asked Questions

How have OKYO shares performed this year?

OKYO Pharma's stock was trading at $1.1499 at the beginning of 2025. Since then, OKYO stock has increased by 89.6% and is now trading at $2.18.

When did OKYO Pharma IPO?

OKYO Pharma (OKYO) raised $2 million in an initial public offering (IPO) on Tuesday, May 17th 2022. The company issued 625,000 shares at $4.00 per share.

Who are OKYO Pharma's major shareholders?

Top institutional investors of OKYO Pharma include Wealth Enhancement Advisory Services LLC (0.03%).
View institutional ownership trends.

How do I buy shares of OKYO Pharma?

Shares of OKYO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of OKYO Pharma own?

Based on aggregate information from My MarketBeat watchlists, some other companies that OKYO Pharma investors own include Meta Platforms (META), Intel (INTC), NVIDIA (NVDA), C3.ai (AI), Bristol Myers Squibb (BMY), Energy Transfer (ET) and Ford Motor (F).

Company Calendar

• Today: 9/10/2025
• Fiscal Year End: 3/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:OKYO
• CIK: 1849296
• Web: www.okyopharma.com
• Phone: 44-20-7495-2379
• Fax: N/A
• Employees: 7
• Year Founded: N/A

Price Target and Rating

• Average Price Target for OKYO Pharma: $7.00
• High Price Target: $7.00
• Low Price Target: $7.00
• Potential Upside/Downside: +217.5%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 1 Analysts

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.40
• Quick Ratio: 0.40

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($0.16) per share
• Price / Book: -13.78

Miscellaneous

• Outstanding Shares: 37,610,000
• Free Float: 22,394,000
• Market Cap: $82.93 million
• Optionable: Not Optionable
• Beta: -0.10